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This work reports the results of an interesting study related to the investigation of interactions of bromocriptine
(BCP) with human serum albumin (HSA) by mathematicall modelling of voltammetric and spectroscopic data into
an augmented data matrix and its resolution by multivariate curve resolution-alternating least squares (MCR-
ALS). The quality of the results obtained by MCR-ALS was examined by MCR-BANDS and its outputs confirmed
the absence of rotational ambiguities in the MCR-ALS results. BCP-HSA interactions were also modeled by mo-
lecular docking methods to verify the results obtained from experimental sections and fortunately, they were
compatible. Hard modeling of the experimental data by EQUISPEC helped us to calculate the binding constant of
the complex formed from BCP-HSA interactions which was in a good agreement with that of calculated from
direct analysis of the experimental data. Finally, with the help of two different amperometric measurements based
on BCP-HSA interactions a novel electroanalytical method was developed for biosensing of HSA in serum samples.1. Introduction
Bromocriptine (BCP, Fig. 1A) as an oral dopamine receptor agonist is
used for the therapy of Parkinson disease [1]. The BCP is a strong in-
hibitor against prolactin formation with therapeutic potency in the
treatment of hyperprolactinemia which is also used in the treatment of
migraine [2, 3, 4, 5, 6]. The effects mentioned above are observed for
BCP because of the ability of BCP to block dopamine receptors and its
interaction with calmodulin-induced activation of phosphodiesterases in
human brain [7, 8].
Human serum albumin (HSA, Fig. 1B) as the most abundant protein in
human blood plasma acts as a carrier for drugs [9, 10, 11, 12, 13, 14, 15].
Free concentration, distribution and metabolism of drugs are highly
depended on their interactions with HSA. On the other side, determi-
nation of the concentration of HSA is important from clinical point of
view, because unusual concentrations of HSA unravel the existence of
some diseases such as diabetes and cardiovascular disease, etc. Common
methods for determination of HSA include LC-MS/MS, capillary.R. Jalalvand).
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evier Ltd. This is an open access aelectrophoresis and immunoassays which suffer from time and cost
therefore, developing novel analytical methods for determination of HSA
which are fast and low-cost is important from clinical point of view.
Generally, interactions of drugs with HSA are investigated by UV-Vis
spectrophotometry [16], FT-IR [17], electrochemistry [18], capillary
electrophoresis [19], HPLC [20] and NMR [21]. Sometimes, instrumental
techniques are assisted by chemometric methods for investigation of
interactions of drugs with HSA [22, 23]. HSA-drug interactions produce a
complicated systemwhich its monitoring needs simultaneous monitoring
of HSA, drug and their complex product. Simultaneous resolution of such
a complex system is quiet challenging therefore, multivariate analysis of
the data is demanded. Multivariate curve resolution-alternating least
squares (MCR-ALS) is a famous chemometric tool which can help us in
resolving HSA-drug interactions to obtain new information about the
studied system.
The steps of this work are including: 1) direct analysis of voltam-
metric and spectroscopic data to obtain some information about BCP-
HSA interactions, 2) mathematical modeling of voltammetric and19
rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
Fig. 1. (A) Molecular structure of BCP and (B) secondary structure of HSA.
Fig. 2. The SEM images captured from the surface of (A) HSA/GCE and (B)
MWCNTs-IL/GCE.
A.R. Jalalvand et al. Heliyon 5 (2019) e02153spectroscopic data to construct an augmented data matrix and its
simultaneous resolution by MCR-ALS for obtaining new information
about BCP-HSA interactions, 3) modeling of BCP-HSA interactions by
molecular docking methods and 5) developing a novel electroanalytical
methodology for electrochemical biosensing of electro-inactive HSA.
2. Experimental
2.1. Experimental details
2.1.1. Chemicals and solutions
HSA, BCP, warfarin (Wr), ibuprofen (Ip), acetic acid, ethanol, dime-
thylformamide (DMF), sodium phosphate monobasic (NaH2PO4), sodium
phosphate dibasic (Na2HPO4), 1-ethyl-3-methylimidazolium bis(tri-
fluoromethylsulfonyl)Imide (IL), dimethyl sulfoxide (DMSO), sodium
hydroxide, phosphoric acid (H3PO4), sodium chloride and hydrochloric
acid were purchased from Sigma. Ionic Liquid Technologies was chosen
as a well-known brand to purchase multiwalled carbon nanotubes
(MWCNTs). Other chemicals were prepared from legal sources. A 0.05 M
phosphate buffer solution (PBS) was prepared from NaH2PO4 and
Na2HPO4 and its pH was adjusted at 7.4 by H3PO4 and NaOH. Stock
solutions of BCP and HSA with a were prepared in the PBS (0.05 M, pH
7.4) and stock solutions of Wr and Ip were prepared in DMSO. To prepare
MWCNTs-IL, 30 mg MWCNTs was added to 1 mL DMFþ50 μL IL and
ultrasonicated for 45 min. All the solutions were prepared by doubly
distilled water (DDW).
A medical diagnostic laboratory provided us three human serum
samples which were centrifuged at 4500 rpm for 20 min and the super-
natants were discarded. To 5 mL of each sample was 45 mL PBS (0.05 M,
pH 7.4) was added and then, each sample was analyzed towards deter-
mination of HSA.
2.1.2. Instruments and softwares
All the electrochemical data were collected by an Autolab
PGSTAT302N-high performance controlled by the NOVA 2.1.2 software.
Electrochemical experiments were performed in an electrochemical cell
containing a bare or modified glassy carbon electrode (GCE), a Pt wire
and an Ag/AgCl electrode acted as working, counter and reference
electrode, respectively. A KYKY-EM 3200 scanning electron microscope
was used to take the SEM images. A Cary Eclipse fluorescence spectro-
photometer equipped with a water bath and a 1.0 cm quartz cell was used
to record the spectrofluorimetric data. A Shimadzu spectrophotometer
equipped with a 1.0 cm quartz cell was used to collect the spectropho-
tometric data. pH adjustments were performed by an ELMEIRON pH-2
meter (CP-411). Molecular structure of the BCP was depicted and opti-
mized by Hyperchem. The PDB file of HSA (PDB Id: 1AO6) was down-
loaded from Brookhaven Protein Data Bank (PDB). For docking of BCP to
HSA, Arguslab software was used. LIGPLOT an automatically program for
plotting protein-ligand interactions [24], was used to plot BCP-HSA in-
teractions. The routines of MCR-ALS and MCR-BANDS were available in
internet [25].
2.1.3. Fabrication of the modified electrodes
A bare GCE was well polished by a silky polishing pad and then,
rinsed with DDW and dried at room temperature. By drop-casting of 10
μL HSA 104 M to the surface of the cleaned bare GCE, the HSA/GCE was
fabricated. To fabricate MWCNTs-IL/GCE, 10 μL MWCNTs-IL was drop-
casted onto the surface of the cleaned GCE. The SEM images of HSA/
GCE and MWCNTs-IL/GCE are shown in Fig. 2.
2.1.4. Procedures
For performing each spectroscopic experiment, different volumes of
HSA or BCP were added to a quartz cell containing 2 mL of HSA or BCP
with a known concentration. Each solution was shaken for 15 s and then,
its spectrum was recorded.
In each voltammetric experiment, 4 mL of HSA or BCP with a known
concentration was added to the electrochemical cell and different vol-
umes of HSA or BCP was added to the cell. Each solution was genteelly
stirred for 1 min and then, its voltammogram was recorded.
2.1.5. Experiments required to build an augmented data matrix
All the experiments used to build an augmented matrix have been
codded in Table 1.
Table 1









DHSAF HSA, 2.0  107 M BCP, 0–1.0  106 M Fluorescence
DHSAUVVis HSA, 1.0  105 M BCP, 0–5.0  105 M UVVis
DHSADPV HSA, 1.0  105 M BCP, 0–5.0  105 M Differential pulse
voltammetry
DHSALSV HSA, 1.0  104 M BCP, 0–5.0  104 M Linear sweep
voltammetry
DHSACV HSA, 1.0  104 M BCP, 0–5.0  104 M Cyclic voltammetry
DBCPF BCP, 1.0  107 M HSA, 0–1.0  107 M Fluorescence
DBCPUVVis BCP, 1.0  104 M HSA, 0–1.0  104 M UVVis
DBCPDPV BCP, 1.0  105 M HSA, 0–1.0  105 M Differential pulse
voltammetry
DBCPLSV BCP, 1.0  104 M HSA, 0–1.0  104 M Linear sweep
voltammetry
DBCPCV BCP, 1.0  104 M HSA, 0–1.0  104 M Cyclic voltammetry
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3.1. Required information about application of MCR-ALS to the
augmented data matrix
There are some works published on application of MCR-ALS in the
analysis of electroanalytical data [26, 27, 28, 29] and in this section, a
summarized description is dedicated. A voltammetric or spectroscopic
data matrix (D (MN), M objects and N variables e.g. wavelength or
potential) can be decomposed by MCR to obtain spectra or voltammo-
grams and concentration profiles according to the following equation:
D¼CST þ E (1)
where C is a (MP) matrix which contains concentration profiles of the P
species, ST is a (PN) matrix containing pure signals and E is a (MN)
matrix which contains residuals. After decomposition of D, ALS as one of
the most important iterative approaches is used to optimize the results of
MCR. Resolution of a chemical system monitored by more than one
instrumental technique by MCR-ALS needs a column- and row-wise
augmented data matrix. In this work, BCP-HSA interactions have been
investigated by differential pulse voltammetry (DPV), linear sweep vol-
tammetry (LSV), cyclic voltammetry (CV), UVVis spectrophotometry and
fluorescence spectroscopy (F). The individual data matrices related to the






















5 (2)where DDPV, DLSV, DCV, DUVVis and DF refer to the data recorded by DPV,
LSV, CV, UVVis and F. C, S and E are concentration, pure signals and
residuals, respectively.
Evolving Factor Analysis (EFA) can be used to determine the number
of species (P) of the augmented data matrix [30, 31, 32], and to obtain an
initial estimation of the concentration profiles. Some constraints are used
during ALS optimization which help to obtain chemically meaningful
results [33]. The lack of fit (lof) is a criterion to evaluate the quality of the
final results. The lof is the difference between the input data (D) and the
data reproduced by MCR-ALS which can be calculated according to the
following equation [34]:










where dij is an element of D and eij is its corresponding residual.
The solutions which are applied to solve Eq. (1) by MCR-ALS are not
unique and may have some rotational and intensity ambiguities. Column-
and row-wise augmentation can be used to shooting this trouble. Matrix
augmentationwhichhelp us to simultaneous resolution of different types of
instrumental data is more powerful than that described by Eq. (1) and can
be used as an efficient strategy for simultaneous resolution of complex data
and to copewith the challenge arising from the small signal shifts observed
in the data. However, because of combination of different types of instru-
mental data, some considerations as follows must not be neglected:
1. Voltammetric and spectroscopic data have different intensities
therefore, normalization of them is required for having similar weight
on the iterative ALS optimization. This goal can be achieved by
dividing each matrix to its maximum value.
2. The augmented matrix which is used as the input of MCR-ALS con-
tains different types of instrumental data therefore, in this case, the
concept of component is complicated. From spectroscopic and vol-
tammetric point of view a component has different meanings. From
spectroscopic point of view, a component is a pure chemical species in
solution [35, 36], but from electrochemical point of view a compo-
nent which is associated to a single electrochemical process can also
be associated adsorption at the electrode surface or capacitive cur-
rents [37, 38].
3. For building an augmented data matrix by the association of indi-
vidual voltammetric and spectroscopic matrices, size of all the
matrices must be equal and a same distribution of the species during
all the experiments is needed. To achieve this goal, a same total
concentration is needed for BCP and HSA in all titrations, but
achieving to this goal is impossible because higher concentrations are
needed for voltammetric experiments than spectroscopic experi-
ments. Therefore, to achieve the goal mentioned above, all the vol-
tammetric and spectroscopic experiments have been performed at
different total concentrations but with the same values of ratio.
4. Results and discussion
4.1. Voltammetric studies of BCP-HSA interactions
4.1.1. Cyclic voltammetry
CV as a powerful electrochemical has been frequently used to inves-
tigate interactions of small molecules with serum albumin [39], there-
fore, we used it to investigate BCP-HSA interactions. To achieve this goal,HSA in the range of 0–1.0  104 M was added to a constant concen-
tration of BCP (1.0 104 M) and the results are shown in Fig. 3A. As can
be seen, the CV response of the BCP is affected by the addition of HSA
which its peak current and peak potential were decreased and increased,
respectively. These phenomena are related to the interactions of BCP
with HSA and change in the molecular environment around the BCP
molecule [40]. Ep and Ep/2 values of the CV response of the BCP at the
GCE surface are 270 and 170 mV, respectively. For an irreversible
oxidation jEpEp/2j ¼ 47.7/αn [41], and α¼ 0.5 [42], nwas calculated to
be 2.07 i.e. ~ 1.
Some information about the type of interactions of a small molecule
with a biological macromolecule could be obtained by immobilizing the
biomacromolecule onto the electrode surface [43, 44]. To achieve this
goal, the response of GCE to BCP (curve a) was compared with that of
Fig. 3. (A) CVs of 1.0  104 M BCP in the presence of increasing concentration of HSA in the range of 0–1.0  104 M, (B) CVs of 2.0  104 M BCP recorded at the
surface of bare GCE (curve a) and HSA/GCE (curve b), (C) LSVs of 1.0  104 M BCP in the presence of increasing concentration of HSA in the range of 0–1.0  104 M
and (D) DPVs of 1.0  105 M BCP in the presence of increasing concentration of HSA in the range of 0–1.0  105 M.
Fig. 4. (A) Fluorescence emission spectra of 2.0  107 M HSA (λex ¼ 280 nm) in the presence of increasing concentration of BCP ranging in 0–1.0  106 M, (B)
effects of Wr (curve a) and Ip (curve b) as site markers on the fluorescence of HSA-BCP, (C) UVVis absorption spectra of 1.0  105 M HSA in the presence of increasing
concentration of BCP ranging in 0–5.0  105 M and (D) DPVs of 1.0  105 M HSA in the presence of increasing concentration of BCP ranging in 0–5.0  105 M.
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A.R. Jalalvand et al. Heliyon 5 (2019) e02153HSA/GCE (curve b), and the results are shown in Fig. 3B. As can be seen,
the CV response of BCP at the surface of HSA/GCE was observed at more
positive potentials than its response at bare GCE. The positive shifts
observed in the CV response of BCP at the surface of HSA/GCE confirmed
that the main interactions of BCP with HSA were hydrophobic in-
teractions [43].
The binding of BCP to HSA/GCE was also investigated by recording
the CV responses of HSA/GCE to different concentrations of BCP (not
shown). The CVs' intensities were increased with increasing BCP con-
centration (CBCP) and subsequently were reached to saturation values.
According to Eq. (4) [45], in which I, Imax, and Kb are referred to peak
current, maximum peak current and binding constant of BCP to
HSA/GCE surface, respectively, CBCP/I on were regressed on CBCP (not
shown) to obtain the Kb value which was calculated to be 5.08  105
mol1 L.
CBCP = I ¼ ð1=KbImaxÞ þ ðCBCP=ImaxÞ (4)
4.1.2. LSV and DPV studies
The LSV and DPV studies of of BCP-HSA interactions were performed
by recording the instrumental signals at GCE obtained by adding HSA to
BCP and the results are shown in Fig. 3C and D, respectively. As can be
seen, the intensity of the CV response of the BCP was decreased and
shifted to more positive potentials by the addition of HSA which may be
related to the embedding of BCP within the HSA structure and its
interaction with HSA or a competitive adsorption may be occurred at the
GCE surface. As reported by the other researchers [46, 47], a low area
from the electrode surface (10%) is covered by the interaction of a low
concentration of a biological macromolecule such as HSA with a small
molecule therefore, adsorption can be neglected and the mentioned
phenomena are related to the interaction of BCP with HSA, but in next
section our studies will ne assisted by chemometric methods to obtain
more information about BCP-HSA interactions.
4.2. Spectroscopic studies
4.2.1. Spectrofluorimetric studies
The spectrofluorimetric data obtained by the titration of 2.0 107 M
HSA prepared in the PBS (0.05 M, pH 7.4) upon addition of BCP in the
range of 0.0–1.0  106 M at three different temperatures (i.e., 298.15,
304.15 and 310.15 K) were recorded and one of them (298.15 K) is
shown in Fig. 4A. The results showed that the fluorescence intensity of
HSA was decreased versus increasing concentration of BCP. The intrinsic
fluorescence of HSA is related to its single tryptophan residue (Trp-214)
whose intensity is decreased by the interaction of a small molecule with
HSA [48, 49, 50]. Fluorescence quenching can be caused by different
molecular interactions such as energy transfer, molecular rearrange-
ments, excited state reactions, complex formation and collisional
quenching, but fluorescence quenching is usually occurred by dynamic
collision and static quenching (complex formation). Usually,
Stern-Volmer equation is used to clarify the mechanism of fluorescence
quenching [51]:
F0 =F ¼ 1þ KSV½Q (5)
where F0 and F are steady-state fluorescence intensities in the absence
and presence of the BCP as quencher (Q), respectively. KSV and [Q] are
the Stern-Volmer quenching constant and concentration of the BCP,Table 2
Stern-Volmer quenching constants at different temperatures related to BCP-HSA
interactions.





respectively. According to Eq. (5), the results of regression of F0/F values
on [Q] (not shown), are presented in Table 2. As can be seen, the KSV
values are decreased with increasing temperature suggesting a static
quenching (complex formation) for BCP-HSA interactions.
4.2.2. Site selectivity of binding of BCP to HSA
There are two sites including site I (hydrophobic sub-domain IIA)
[52] and Sudlow's sites II (sub-domain IIIA) [53] in HSA which enable
small molecules for binding with HSA. To clarify the location of binding
of BCP to HSA, two competitive experiments were designed where two
site markers includingWr (marker of site I) and Ip (marker of site II) were
used to compete with BCP for binding with HSA. To perform these ex-
periments, Wr or Ip in the range of 0.0–2.0  107 M was added to a
mixture containing both of BCP and HSA in which BCP concentration
(2.0  107 M) was four times higher than HSA (5.0  108 M). Then,
(F1/F2)  100 values (F1 and F2 are the fluorescence intensity in the
absence and presence of site marker, respectively) were plotted versus
[Site Marker]/[HSA] as shown in Fig. 4B. As can be seen, the (F1/F2) 
100 was decreased by the addition of Wr to the HSA-BCP solution
(Fig. 4B, curve a) which showed BCP-HSA interactions were affected by
the addition of Wr. While, the mentioned system was not affected by the
addition of Ip (Fig. 4B, curve b) which indicated that the Ip did not
compete with BCP for binding with HSA. According to the results
mentioned above, we can conclude that the hydrophobic pocket in
sub-domain IIA of HSA is the main location for binding of BCP with HSA.
4.2.3. Spectrophotometric studies
UVVis spectrophotometric experiments were also used to investigate
of BCP-HSA interactions. Spectrophotometric spectra were recorded by
the addition of BCP in the range of 0.0–5.0  105 M to a constant
concentration of HSA (1.0  105 M) and the results are shown in
Fig. 4C. An absorption peak observed at 280 nm is related to HSA whose
position and intensity were changed in the presence of BCP which were
related to interactions of BCP with HSA.
4.2.4. Fluorescence energy transfer from HSA to BCP
Fluorescence energy transfer (FRET) is a global technique for the
measurement of molecular distance [54]. Eq. (6) describes efficiency (E)
of FRET which is depended on inverse sixth power of the distance be-
tween donor and acceptor (r, Forster distance) [55], Forster radius (R0,
Eq. (7)), overlapping of emission and absorption of donor and acceptor,








R60 ¼ 8:8 1025k2n4JΦ (7)
k2, n, Φ and J have their conventional meaning and J can be calculated






where F(λ) and ε are the fluorescence intensity of the donor and molar
absorption coefficient of the acceptor, respectively. According to the
previous work [56] reported in the literature, k2, n and Φ are 2/3, 1.336
and 0.118, respectively, which were used to calculate the values of J, R0,
E and r which were to be 4.36  1014 cm3M1, 3.13 nm, 0.08 and 4.7
nm, respectively. According to the values calculated for r which is less
than 8 nm we can conclude that the energy transfer can be occurred from
HSA to BCP [57].
4.3. Building an augmented data matrix
In this section, spectroscopic and voltammetric data were collected
Fig. 5. (A) LSVs of 1.0  104 M HSA in the
presence of increasing concentration of BCP
ranging in 0–5.0  104 M, (B) CVs of 1.0  104
M HSA in the presence of increasing concentra-
tion of BCP ranging in 0–5.0  104 M, (C) UVVis
absorption spectra of 1.0  104 M BCP in the
presence of increasing concentration of BCP
ranging in 0–1.0  104 M BCP and (D) fluores-
cence emission spectra of 1.0  107 M BCP in
the presence of increasing concentration of HSA
ranging in 0–1.0  107 M.
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MCR-ALS which will be more explained in next sections.
4.3.1. MCR-ALS results
Interactions of BCP-HSA were further investigated by MCR-ALS
which helped us to obtain more information about stoichiometry of the
complex species involved and the relative concentrations of the various
species. This goal was achieved by building a column- and row-wise
augmented data matrix by collecting data matrices obtained by DPV
(DBCPDPV , Fig. 3D, D
HSA
DPV , Fig. 4D), LSV (D
BCP
LSV , Fig. 3C, D
HSA
LSV , Fig. 5A), CV
(DBCPCV , Fig. 3A, D
HSA
CV , Fig. 5B), UVVis (D
BCP
UVVis, Fig. 4C, D
HSA
UVVis, Fig. 5C) and
F (DHSAF , Fig. 4A, D
BCP
F , Fig. 5D) and then, the augmented data matrix was
analysed by MCR-ALS.
The first step was including determination of the number of species by
singular value decomposition (SVD) and which detected three main
species and we guess that they may be related to BCP, HSA and one HSA-
BCPm complex species. The second step was devoted to find an initial
estimation of the concentration profiles with the help of EFA. The EFA is
able to work with full rank data sets and is not able to find useful in-
formation by the analysis of rank-deficient data andmatrix augmentationFig. 6. (A) and (B) concentration profiles of the species involved which were extra
olution of voltammetric and spectroscopic data.
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can tackle this trouble [58]. In MCR-ALS application of constraints dur-
ing ALS optimization can help us to obtain reliable results. In this work,
due to having CV data which contain negative values, the non-negativity
constraint can only apply to the concentration profiles. Because of
recording data matrices at different concentration levels, a closure
constraint cannot be applied. The ALS was begun for optimizing the MCR
results with the help of constraints mentioned above and the lofwas used
as a criterion to evaluate the goodness of the fitting model and here, the
lof was found to be 3.60% which is an acceptable value for explaining
almost all of the variability in the experimental data.
The results of MCR-ALS are shown in Figs. 6 and 7. Fig. 6A and B show
the concentration profiles of the species involved and from Fig. 6A it can
be concluded that by the addition of HSA to BCP, concentration of BCP is
decreased and a complex species is formed whose concentration is
increased and reached equilibrium at the ratio of [HSA]/[BCP]~0.5. The
maximum concentration of the complex species at [HSA]/[BCP]~0.5
confirms this species is a HSA-BCP2 complex specie. By casting a look at
Fig. 6B it can be seen that the ratio of [BCP]/[HSA]~2 is critical in which
concentration of the BCP reaches to a minimum while concentrations of
HSA and complex species are sharply decreased and increased,cted by applying MCR-ALS to the augmented data matrix for simultaneous res-
Fig. 7. (A)–(E) extracted signals of different species involved in DPV, LSV, CV, F and UVVis experiments, respectively, and (F) plot of coinciding experimental (points)
and calculated data (line).
Table 3
Results of calculating binding constant by EQUISPEC.
Analyzed matrix Kb
HSA-BCP2
½DBCPDPVDBCPLSVDBCPCV DBCPF DBCPUVVis 5.11  105












5 5.12  105
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complex formation is occurred at this ratio and which confirms that the
complex specie is HSA-BCP2. Therefore, according to the results of MCR-
ALS, we can say that there are three species in the system studied here
including free BCP, free HSA and a HSA-BCP2 complex species. Pure
voltammetric and spectral profiles resolved by MCR-ALS can be observed
in Fig. 7A–E. Voltammetric profiles show that the HSA is electro-inactive
while the complex specie is electroactive and this may be related to
accessibility of the tryptophan and tyrosine residues of HSA by unfolding
its structure upon reacting with BCP. Therefore, it can be concluded that
embedding of two BCP molecules in HSA structure unfolds the HSA
structure which opens the pathways for accessibility of tryptophan and
tyrosine residues to be oxidizable at the electrode surface. A plot with
coincided experimental and theoretical data which is shown in Fig. 7F by
which the quality of the fitting process is guaranteed.
4.3.2. Application of MCR-BANDS to the verification of the MCR-ALS
results
As stated in previous sections, application of constraints can help us to
obtain meaningful results which is an important advantage of MCR rather
than the other bilinear methods [59]. However, sometimes, MCR used a
band of feasible solutions instead of a unique solution which may cause
some ambiguities in the results [60]. Therefore, the presence of ambi-
guities in MCR-ALS results must be verified and MCR-BANDS as an
efficient chemometric tool has been developed to calculate maximum
and minimum of the relative contribution of the components to estimate7
the feasible solutions [59, 61] which can help us to estimate the extent of
rotational ambiguities [62]. In this work, to estimate the extent of rota-
tional ambiguities in MCR-ALS results, the data matrix reproduced by
MCR-ALS was used as the input of MCR-BANDS and analysed under the
same constraints used for MCR-ALS. The maximum relative contribution
function (fmax) and minimum relative contribution function (fmin) for
each species were calculated: HSA (fmax ¼ 0.348 and fmin ¼ 0.348), BCP
(fmax ¼ 0.291 and fmin ¼ 0.291) and HSA-BCP2 (fmax ¼ 0.355 and fmin ¼
0.355). As can be seen, there is no difference between the fmax and fmin for
all the contributing species which confirm that there isn't any rotational
ambiguity [59]. The good quality for the results of MCR-ALS are related
to matrix augmentation and using suitable constraints for the resolution.
4.4. Hard-modeling
Four building a hard-model, definition of the stoichiometry of the
A.R. Jalalvand et al. Heliyon 5 (2019) e02153species and estimation of the binding constant are necessary and then,
decomposition of data matrix D can be performed according to Eq. (1).
The first step is focused on obtaining an estimation for the concentration
profiles (C) and then, the pure spectra (ST) can be calculated by least
squares fitting with the best matching of C and D. The differences be-
tween input data matrix and the reproduced data matrix are gathered in
the residual data matrix (E). Optimization procedure can be performed
by the hard-modeling algorithm using tuning the defined stoichiometries
to obtain a desired level of residuals. More details can be found in
Ref. [63].
Here, EQUISPEC was used calculate the binding constants and the
results are collected in Table 3. As can be seen, there is a good agreement
between the results of EQUISPEC and those of Section 4.1.1.4.5. Molecular docking
In this study, the Arguslab program was used to realize the binding
mode of BCP at the active site of HSA. The main aspect for the ligand
docking postures was considering the effective interaction of the drug
with the various amino acid residues in the active site. The applied box
size was 60  60  60 Å and grid resolution was 0.4 Å. Docking simu-
lations were performed by selecting ArgusDock as the docking engine
flexible for the drug. Finally, the AScore was used as the scoring function
and the results with different views are shown in Fig. 8A–C. The results
showed that the binding sites were Lys 199, Tyr 214, Leu 198, Arg 218,
Val 455, Lys 195, Arg 222, Asp 451, Ser 192, Pro 447, Tyr 452, Glu 292,
His 288, Ala 191, Cys 448, Phe 157, Glu 188 and Lys 436. The ΔG was
-29.01 kJ mol1 and BCP was bound to sub-domain IIA of HSA. The
LIGPLOT program was also used to more investigation of BCP-HSA in-
teractions and the results are shown in Fig. 8D. LIPLOT shows the hy-
drophobic interactions and hydrogen bindings and according to its
outputs three hydrogen bonds between BCP and Lys 436, BCP and Lys
195 and BCP and Arg 218 were observed and hydrophobic interactions
were observed between BCP and Glu 188, Ser 192, Glu 292, Ala 191, Trp
214, Val 455, Tyr 452 and Cys 448.Fig. 8. Computer-generated models of binding BCP to HSA presented by: (A) pose org
HSA interactions presented by LigPlot program.
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4.6. Analytical characterizations
The aim of this section is to develop a novel electroanalytical meth-
odology for sensitive determination of HSA based on BCP-HSA in-
teractions. To achieve more sensitivity amperometric measurements
were chosen and the GCE was modified [64, 65, 66, 67, 68, 69].
4.6.1. Amperometric measurements
For electrochemical biosensing of the electro-inactive HSA, two
different amperometric experiments were performed in the absence and
presence of HSA. One amperometric measurement was performed under
addition of nineteen different concentrations of BCP ranging in 2–100 μM
upon applying a potential of 0.12 V (oxidation potential of BCP at the
surface of MWCNTs-IL/GCE) and the related i-t data were depicted in
Fig. 9A. The second amperometric experiment was performed by the
addition of BCP with the same concentrations used for the first experi-
ment but in the presence of increasing concentration of HSA in the range
of 2–98 nM. The i*-t curve related to the second experiment is depicted in
Fig. 9B. A calibration curve for electrochemical biosensing of HSA was
built based on regression ofΔi¼ i-i* values HSA concentration which can
be seen in Fig. 9C. Two linear ranges including 2–16 nM and 16–98 nM
were obtained and sensitivity and limit of detection (LOD) of the sensor
were calculated to be 2.15 μA nM1 and 1 nM (according to 3SD/m,
where SD is the standard deviation of the intercept and m is the slope of
the calibration curve), respectively.
4.6.2. Interference study
In order to investigate the selectivity of the sensor response to HSA
in the presence of interfering species, its response to 10 nM HSA in the
presence of 100-fold interfering species including (a) cysteine, (b)
tyrosine, (c) histidine, (d) valine, (e) methionine, (f) proline, (g)
phenylalanine, (h) egg albumin, (i) chloramphenicol, (j) amoxicillin, (k)
vitamin C and (l) vitamin B12 was examined and the results are shown
in Fig. 9D. The results showed that the sensor had a selective response
to HSA.anizer view, (B) hydrophobicity view and (C) secondary structure view. (D) BCP-
Fig. 9. (A) Amperometric responses recorded by
MWCNTs-IL/GCE upon increasing concentration
of BCP, (B) same as (A) but, in the presence of
increasing concentration of HSA, (C) regression of
Δi ¼ i-i* values on concentrations of HSA, first
range: Δi ¼ 2.1511CHSAþ0.9602, R2 ¼ 0.9874,
second range: Δi ¼ 0.9691CHSAþ15.34, R2 ¼
0.9977, (D) amperometric responses of the sensor
to HSA and interfering species and (E) examina-
tion of the stability of the sensor response to HSA
by weekly measurement of its response during six
weeks.
Table 4
Results of the analysis of human serum samples by the reference method and
proposed method in this study.
Sample Found by the proposed method in this
study (n ¼ 4)
Found by the reference
method (n ¼ 4)
Serum
1
6.91 (0.05)  104 M 7.01 (0.03)  104 M
Serum
2
7.11 (0.04)  104 M 7.08 (0.02)  104 M
Serum
3
7.54 (0.02)  104 M 7.77 (0.05)  104 M
A.R. Jalalvand et al. Heliyon 5 (2019) e021534.6.3. Stability, repeatability and reproducibility
Stability of a newly developed sensor is a critical characteristic which
must be investigated before advising its capability for the analysis of real
samples. Therefore, to achieve this goal, the sensor was applied to the
determination of 70 nM HSA for six weeks and its response was weekly
recorded and the data are shown in Fig. 9E. The results showed that the
sensor retained 95.4% of its original response which guaranteed the
stability of the sensor. The response of the sensor to 70 nM HSA was also
examined for ten times during a day and our records confirmed a good
relative standard deviation (RSD) value of 3.33% which confirmed a
repeatable response for the sensor. The next attempt was focused on the
examination of the reproducibility of the sensor and to achieve this goal,
six sensors fabricated by the same procedure were applied to the deter-
mination of 70 nM HSA. The RSD value was calculated to be 3.78%
which suggested a reproducible response for the developed sensor in this
study.
4.6.4. Validation of the developed method
In this section, the sensor was applied to the analysis of real samples
and its results were compared with a reference method based on capillary
electrophoresis. The results are presented in Table 4. As can be seen, the
results obtained by the two methods are in a good agreement.9
5. Conclusions
In the present study, BCP-HSA interactions were investigated by
experimental and theoretical methods. The first attempt was focused on
recording electrochemical and spectroscopic data to obtain some infor-
mation about the mentioned interactions. Then, electrochemical and
spectroscopic data were combined to build an augmented data matrix
which were analysed by MCR-ALS to obtain more information which
could not be obtained by direct analysis of the data. The next attempt was
focused on modeling of the interactions of BCP with HSA by molecular
A.R. Jalalvand et al. Heliyon 5 (2019) e02153docking methods and the outputs of this section was used to verify the
results of experimental sections. Finally, a novel method based on BCP-
HSA interactions was developed for sensitive electrochemical determi-
nation of electro-inactive HSA. This study was a thorough which traveled
from bio-interaction to biosensing and definitely will be extended in
future to develop more interesting studies.
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